Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.57)
# 254
Out of 4,981 analysts
129
Total ratings
47.75%
Success rate
42.73%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $14.40 | +94.44% | 1 | Sep 12, 2025 | |
| ACTU Actuate Therapeutics | Initiates: Buy | $20 | $7.03 | +184.50% | 1 | Aug 26, 2025 | |
| ALT Altimmune | Maintains: Buy | $20 → $18 | $3.59 | +401.39% | 10 | Aug 13, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $60 → $85 | $49.01 | +73.43% | 2 | Jul 8, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.23 | +306.50% | 2 | Jun 16, 2025 | |
| MGNX MacroGenics | Maintains: Neutral | $5 → $3 | $1.56 | +92.31% | 2 | May 20, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Buy | $422 → $460 | $425.60 | +8.08% | 12 | May 2, 2025 | |
| HROW Harrow | Maintains: Buy | $69 → $65 | $42.82 | +51.80% | 2 | Apr 1, 2025 | |
| VXRT Vaxart | Maintains: Buy | $2.5 → $2 | $0.37 | +445.63% | 6 | Mar 27, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $11 → $20 | $8.07 | +147.99% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.35 | +122.22% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $13.16 | +165.96% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $28.67 | +32.54% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $24.09 | +298.59% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.54 | -2.60% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $8.08 | +221.78% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $22.02 | +49.90% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $31.75 | +7.09% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $49.44 | +86.08% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $25.70 | +444.75% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $2.99 | +2,910.03% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.45 | +3,495.51% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.64 | +204.88% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.08 | +2,015.38% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $3.55 | +2,435.21% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.97 | +255.33% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.58 | +284,710.13% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.76 | +153,309.09% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $18.13 | +324.71% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.46 | +98,530.14% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $4.50 | -11.11% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $98.93 | -60.58% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.33 | +684.68% | 1 | Mar 13, 2020 |
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $14.40
Upside: +94.44%
Actuate Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $7.03
Upside: +184.50%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.59
Upside: +401.39%
Nektar Therapeutics
Jul 8, 2025
Maintains: Buy
Price Target: $60 → $85
Current: $49.01
Upside: +73.43%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.23
Upside: +306.50%
MacroGenics
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.56
Upside: +92.31%
Madrigal Pharmaceuticals
May 2, 2025
Reiterates: Buy
Price Target: $422 → $460
Current: $425.60
Upside: +8.08%
Harrow
Apr 1, 2025
Maintains: Buy
Price Target: $69 → $65
Current: $42.82
Upside: +51.80%
Vaxart
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.37
Upside: +445.63%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $8.07
Upside: +147.99%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.35
Upside: +122.22%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $13.16
Upside: +165.96%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $28.67
Upside: +32.54%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $24.09
Upside: +298.59%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.54
Upside: -2.60%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $8.08
Upside: +221.78%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $22.02
Upside: +49.90%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $31.75
Upside: +7.09%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $49.44
Upside: +86.08%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $25.70
Upside: +444.75%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $2.99
Upside: +2,910.03%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.45
Upside: +3,495.51%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.64
Upside: +204.88%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.08
Upside: +2,015.38%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $3.55
Upside: +2,435.21%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.97
Upside: +255.33%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.58
Upside: +284,710.13%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.76
Upside: +153,309.09%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $18.13
Upside: +324.71%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.46
Upside: +98,530.14%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $4.50
Upside: -11.11%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $98.93
Upside: -60.58%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.33
Upside: +684.68%